Quicker, deeper and stronger imaging: A review of tumor-targeted, near-infrared fluorescent dyes for fluorescence guided surgery in the preclinical and clinical stages

Jiao, Jianhua; Zhang, Jingliang; Fa, Yang; Song, Wei; Han, Donghui; Wen, Weihong; Qin, Weijun

doi:10.1016/j.ejpb.2020.05.002

Cited by 49 publications

(25 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from the extra costs and logistic planning, this leads to an extra burden for pediatric OS, ES, and RMS patients. Therefore, smaller targeting moiety alternatives such as antibody fragments, peptide conjugates and small molecule conjugates may be advantageous for FGS [33]. Briefly, tracers smaller than 60 kDa are generally cleared via the kidneys instead of via the liver, resulting in faster blood clearance from non-targeted tissues.…”

Section: Disadvantages Of Using Antibodies For Fluorescence-guided Surgery and Their Alternativesmentioning

confidence: 99%

“…Briefly, tracers smaller than 60 kDa are generally cleared via the kidneys instead of via the liver, resulting in faster blood clearance from non-targeted tissues. Consequently, a high tumor-to-background contrast can be attained within hours after the administration of a tumor-specific smaller targeting moiety alternative-based tracer [26,33,125].…”

Section: Disadvantages Of Using Antibodies For Fluorescence-guided Surgery and Their Alternativesmentioning

confidence: 99%

“…Its benefits have been shown, amongst others, in assessing perfusion, identifying liver metastases and visualizing sentinel lymph nodes [23,31]. Targeted tracers contain fluorophores conjugated to cancer-specific targeting moieties such as antibodies, peptides or small molecule inhibitors [32,33]. While FGS has been investigated with promising results in various types of malignancies, information regarding its application in pediatric sarcomas such as OS, ES, and RMS is relatively scarce [34].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review

et al. 2021

View full text Add to dashboard Cite

Sarcomas are a rare heterogeneous group of malignant neoplasms of mesenchymal origin which represent approximately 13% of all cancers in pediatric patients. The most prevalent pediatric bone sarcomas are osteosarcoma (OS) and Ewing sarcoma (ES). Rhabdomyosarcoma (RMS) is the most frequently occurring pediatric soft tissue sarcoma. The median age of OS and ES is approximately 17 years, so this disease is also commonly seen in adults while non-pleiomorphic RMS is rare in the adult population. The mainstay of all treatment regimens is multimodal treatment containing chemotherapy, surgical resection, and sometimes (neo)adjuvant radiotherapy. A clear resection margin improves both local control and overall survival and should be the goal during surgery with a curative intent. Real-time intraoperative fluorescence-guided imaging could facilitate complete resections by visualizing tumor tissue during surgery. This review evaluates whether non-targeted and targeted fluorescence-guided surgery (FGS) could be beneficial for pediatric OS, ES, and RMS patients. Necessities for clinical implementation, current literature, and the positive as well as negative aspects of non-targeted FGS using the NIR dye Indocyanine Green (ICG) were evaluated. In addition, we provide an overview of targets that could potentially be used for FGS in OS, ES, and RMS. Then, due to the time- and cost-efficient translational perspective, we elaborate on the use of antibody-based tracers as well as their disadvantages and alternatives. Finally, we conclude with recommendations for the experiments needed before FGS can be implemented for pediatric OS, ES, and RMS patients.

show abstract

Section: Disadvantages Of Using Antibodies For Fluorescence-guided Surgery and Their Alternativesmentioning

confidence: 99%

Section: Disadvantages Of Using Antibodies For Fluorescence-guided Surgery and Their Alternativesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Fluorescent chemosensors have already shown great promise in real-world situations and applications, including but not limited to: the detection of environmental waste pollutants, detection of chemical warfare agents, fluorescence guided surgery, whole body diagnostic imaging, in vivo flow cytometry, and eHealth diagnostic devices (point of care (POC) testing) (Christodouleas et al, 2018;Jiao et al, 2020;Wei and Xunbin, 2021). In addition, colorimetric sensors have been established as potentially attractive sensing platforms due to their low cost as well as their capability to respond to stimuli with concurrent colour (UV-Vis) changes that could be discerned using the naked eye (López-Alled et al, 2017;Gwynne et al, 2021a;Gwynne et al, 2021b).…”

Section: Introductionmentioning

confidence: 99%

Fluorescent Chemosensors for Ion and Molecule Recognition: The Next Chapter

et al. 2021

View full text Add to dashboard Cite

Over the past 30 years fluorescent chemosensors have evolved to incorporate many optical-based modalities and strategies. In this perspective we seek to highlight the current state of the art as well as provide our viewpoint on the most significant future challenges remaining in the area. To underscore current trends in the field and to facilitate understanding of the area, we provide the reader with appropriate contemporary examples. We then conclude with our thoughts on the most probable directions that chemosensor development will take in the not-too-distant future.

show abstract

“…These biomarkers form the basis for tumor-targeted nuclear and fluorescence imaging in various malignancies, including PDAC [ 34 , 42 , 43 , 44 ]. Molecular imaging of oncological targets has been of particular interest in the past decade: multiple (pre)clinical trials have shown promising results for PDAC-targeted PET/CT and NIR-imaging, for diagnostic as well as therapeutic purposes [ 45 , 46 , 47 , 48 ].…”

Section: Introductionmentioning

confidence: 99%

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy

Dam

Vuijk

Stibbe

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Despite recent advances in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC), overall survival remains poor with a 5-year cumulative survival of approximately 10%. Neoadjuvant (chemo- and/or radio-) therapy is increasingly incorporated in treatment strategies for patients with (borderline) resectable and locally advanced disease. Neoadjuvant therapy aims to improve radical resection rates by reducing tumor mass and (partial) encasement of important vascular structures, as well as eradicating occult micrometastases. Results from recent multicenter clinical trials evaluating this approach demonstrate prolonged survival and increased complete surgical resection rates (R0). Currently, tumor response to neoadjuvant therapy is monitored using computed tomography (CT) following the RECIST 1.1 criteria. Accurate assessment of neoadjuvant treatment response and tumor resectability is considered a major challenge, as current conventional imaging modalities provide limited accuracy and specificity for discrimination between necrosis, fibrosis, and remaining vital tumor tissue. As a consequence, resections with tumor-positive margins and subsequent early locoregional tumor recurrences are observed in a substantial number of patients following surgical resection with curative intent. Of these patients, up to 80% are diagnosed with recurrent disease after a median disease-free interval of merely 8 months. These numbers underline the urgent need to improve imaging modalities for more accurate assessment of therapy response and subsequent re-staging of disease, thereby aiming to optimize individual patient’s treatment strategy. In cases of curative intent resection, additional intra-operative real-time guidance could aid surgeons during complex procedures and potentially reduce the rate of incomplete resections and early (locoregional) tumor recurrences. In recent years intraoperative imaging in cancer has made a shift towards tumor-specific molecular targeting. Several important molecular targets have been identified that show overexpression in PDAC, for example: CA19.9, CEA, EGFR, VEGFR/VEGF-A, uPA/uPAR, and various integrins. Tumor-targeted PET/CT combined with intraoperative fluorescence imaging, could provide valuable information for tumor detection and staging, therapy response evaluation with re-staging of disease and intraoperative guidance during surgical resection of PDAC. Methods: A literature search in the PubMed database and (inter)national trial registers was conducted, focusing on studies published over the last 15 years. Data and information of eligible articles regarding PET/CT as well as fluorescence imaging in PDAC were reviewed. Areas covered: This review covers the current strategies, obstacles, challenges, and developments in targeted tumor imaging, focusing on the feasibility and value of PET/CT and fluorescence imaging for integration in the work-up and treatment of PDAC. An overview is given of identified targets and their characteristics, as well as the available literature of conducted and ongoing clinical and preclinical trials evaluating PDAC-targeted nuclear and fluorescent tracers.

show abstract

Quicker, deeper and stronger imaging: A review of tumor-targeted, near-infrared fluorescent dyes for fluorescence guided surgery in the preclinical and clinical stages

Cited by 49 publications

References 158 publications

Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review

Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review

Fluorescent Chemosensors for Ion and Molecule Recognition: The Next Chapter

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy

Contact Info

Product

Resources

About